Atherosclerosis and cardiovascular risk reduction with PPAR agonists.
Peroxisome proliferator-activated receptors (PPARs) are transcriptional factors belonging to the nuclear receptor superfamily. Three isoforms, PPARalpha, PPARgamma, and PPARdelta, which are encoded by separate genes, have been identified. The PPARs act as gene regulators of various metabolic pathways in energy and lipid metabolism, glucose homeostasis, adipogenesis, and inflammation. Two key classes of synthetic compounds, fibrates and thiazolidinediones (glitazones), activate PPARalpha and PPARgamma, respectively. Both of these drugs have several properties that prevent atherosclerosis in the vascular wall and reduce the levels of risk factors for cardiovascular disease. However, clinical trials have not produced convincing evidence that cardiovascular disease is prevented with the use of PPARalpha and PPARgamma agonists.
Kuusisto
Johanna
J
Department of Medicine, University of Kuopio and Kuopio University Hospital, POB 1777, FIN-70211 Kuopio, Finland.
Andrulionyte
Laura
L
Laakso
Markku
M
D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D050197:Atherosclerosis / Q000097:blood / Q000188:drug therapy*; D002318:Cardiovascular Diseases / Q000097:blood / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D002995:Clofibric Acid / Q000627:therapeutic use*; D006801:Humans; D047492:Peroxisome Proliferator-Activated Receptors / Q000819:agonists* / Q000235:genetics / Q000502:physiology; D040242:Risk Reduction Behavior; D045162:Thiazolidinediones / Q000627:therapeutic use*
D000924:Anticholesteremic Agents; D047492:Peroxisome Proliferator-Activated Receptors; D045162:Thiazolidinediones; D002995:Clofibric Acid